Previous 10 | Next 10 |
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , March 1, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineer...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Virtual R&D...
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy PR Newswire SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform techn...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Febr...
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium P-PSMA-101 demonstrated strong anti-tumor activity and induced durable responses at low doses in heavily pretreated patients with mCRPC 10/14 (71%) evalua...
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 PR Newswire SAN DIEGO , Feb. 9, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage b...
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors PR Newswire SAN DIEGO , Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), ...
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting P-BCMA-101 demonstrated strong anti-tumor activity and was well tolerated in nearly 100 patients with R/R multiple myeloma at the time of d...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Inc. Website:
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...